By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celtaxsys, Inc. 

ATDC Biosciences Center
311 Ferst Drive
Atlanta  Georgia  30332  U.S.A.
Phone: 404-920-0700 Fax: 404-920-0701



Start Up

Company News
Celtaxsys, Inc. Begins U.S. Enrollment For Phase 2 Trial Of Acebilustat Anti-Inflammatory Therapy For Cystic Fibrosis 10/8/2015 10:54:22 AM
Celtaxsys, Inc. Gains FDA Clearance For Landmark Phase 2 Trial Of Anti-Inflammatory Treatment For Cystic Fibrosis (CF) 7/6/2015 6:15:34 AM
Celtaxsys, Inc. Secures $45M In Capital To Fund Novel Anti-Inflammatory Phase 2 Programs In Cystic Fibrosis And Acne 6/8/2015 7:01:56 AM
Celtaxsys, Inc. Receives $5M Research Award To Advance Once Daily, Oral Anti-Inflammatory Medicine Into Phase 2 CF Patient Lung Function Preservation Trial 6/2/2015 11:20:47 AM
Celtaxsys, Inc. Has Regulatory Clearance To Begin Phase 2 Trial Of Oral CTX-4430 Anti-Inflammatory Therapy For Moderate To Severe Acne Vulgaris - Recruitment Of Patients To Commence Immediately 4/7/2015 12:32:05 PM
Celtaxsys, Inc. Lead Candidate Granted Orphan Designation In Cystic Fibrosis By FDA 2/3/2015 10:39:07 AM
Celtaxsys, Inc. Announces Sanjeev Ahuja As Chief Medical Officer 11/7/2014 8:23:24 AM
Celtaxsys, Inc. Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients 10/11/2013 9:02:03 AM
Celtaxsys, Inc. Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430 9/17/2013 8:30:32 AM
Celtaxsys, Inc. Restructures Management and Operations; CEO, CTO Out 9/10/2013 7:15:22 AM